Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
61.8M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+3.38M
-
Total reported value, excl. options
-
$264M
-
Value change
-
+$18.2M
-
Put/Call ratio
-
0.22
-
Number of buys
-
52
-
Number of sells
-
-18
-
Price
-
$5.30
Significant Holders of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) as of Q3 2024
91 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
of 61.8M outstanding shares and own 80.47% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.6M shares), Avoro Capital Advisors LLC (5.79M shares), FMR LLC (5.1M shares), BAKER BROS. ADVISORS LP (4.92M shares), BlackRock, Inc. (2.9M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.66M shares), VANGUARD GROUP INC (2.53M shares), Aisling Capital Management LP (1.47M shares), and Alphabet Inc. (1.46M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.